Skip to main content
. Author manuscript; available in PMC: 2009 Dec 27.
Published in final edited form as: Pharm Res. 2009 Mar 4;26(6):1432–1445. doi: 10.1007/s11095-009-9853-y

Fig. 5.

Fig. 5

Targeted transduction of lentiviral vectors in vitro. (a) Fresh unconcentrated lentiviral vectors either bearing an OKT3 antibody and a fusogen (FUGW/OKT3+fusogen), or bearing a non-relevant antibody (Ab, no specificity to CD3) and a fusogen (FUGW/Ab+fusogen), were added to transduce 0.2 × 106 Jurkat.CD3 cells or Jurkat cells. Transduction with lentiviral vectors bearing an OKT3 antibody only (FUGW/OKT3) or bearing the VSVG (FUGW/VSVG) were used as controls. Three days post-transduction, the transduction efficiency was measured by FACS analysis of the percentage of cells expressing GFP. Shaded column: transduction on Jurkat.CD3 cells; Open column: transduction on control Jurkat cells. (b) Specific viral titers for various engineered lentiviral vectors based on both Jurkat.CD3 and Jurkat cells. (c) Kinetics of the transgene expression in Jurkat.CD3 cells transduced with the targeting lentiviral vectors. Jurkat.CD3 cells were transduced with FUGW/OKT3+SV3 and continuously cultured for a month. GFP expression was determined by FACS at the indicated day.